Market Performance - The Hang Seng Healthcare Index decreased by 1.16% as of October 10, 2025, with mixed performance among constituent stocks [2] - The Hang Seng Medical ETF (513060) fell by 1.24%, with a latest price of 0.72 yuan, but has seen a cumulative increase of 25.95% over the past three months [2] - The CSI Pharmaceutical 50 Index dropped by 1.58%, with the Medical 50 ETF (159838) down by 1.50%, latest price at 0.66 yuan, and a 0.91% increase over the past two weeks [6] Key Events - Novo Nordisk announced the acquisition of Akero Therapeutics for up to $5.2 billion, enhancing its position in the metabolic disease sector, particularly in non-alcoholic fatty liver disease, obesity, and diabetes [6] - Wuhan East Lake High-tech Zone introduced measures to support the development of brain-computer interface technology, aiming to attract research institutions and companies to accelerate innovation in high-end medical devices and neuroengineering [6] - Changfeng Pharmaceutical successfully listed on the Hong Kong Stock Exchange, indicating strong market interest in respiratory drugs and inhalation delivery technology [7] Institutional Insights - The global pharmaceutical sector continues to exhibit a structural trend of "innovation focus + policy catalysis," with increased attention on metabolic disease pipelines following Novo Nordisk's acquisition [7] - The implementation of brain-computer interface policies highlights national strategic support for cutting-edge medical technology, potentially boosting innovation in medical devices and neuroregulation [7] - The listing of Changfeng Pharmaceutical reflects a recovery trend for new pharmaceutical stocks in Hong Kong, with a shift in funding focus from traditional pharmaceuticals to innovative technologies and differentiated pipelines [7] Related ETFs - The Hang Seng Medical ETF (513060) tracks the Hang Seng Healthcare Index, covering core assets in Hong Kong's healthcare sector [8] - The Hong Kong Innovative Drug Selection ETF (520690) closely follows the Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index, focusing on leading innovative drug companies [9] - The Medical 50 ETF (159838) tracks the CSI Pharmaceutical 50 Index, encompassing major players in the pharmaceutical and healthcare sectors [9]